Sign in

Research summary ·

Pertuzumab in HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Written based on 1 research study on PubMed, searched on 11 Nov 2026.

What was studied

This meta-analysis looked at pertuzumab in HER2-positive breast cancer. Pertuzumab with trastuzumab blocks HER2 in 2 ways. Past results varied. The team searched several databases, including PubMed and Scopus. It included randomised trials. Quality was rated with ROB-2 and certainty with GRADE. Data were pooled in R. The review covered 8 trials with 8367 patients.

What they found

Pertuzumab-based regimens were linked to better overall survival. In locally advanced or metastatic disease, the hazard ratio was 0.71. The range ran from 0.65 to 0.77. For neoadjuvant or adjuvant use, the hazard ratio was 0.81. This was not significant. Progression-free survival was also better, with a hazard ratio of 0.74. Any adverse events did not differ significantly between groups. The risk ratio was 1.01. Severe adverse events of grade 3 or higher did not differ either. That risk ratio was 0.99.

What it means for patients

The authors say pertuzumab-based dual HER2 blockade was linked to significant gains. These were in overall and progression-free survival. They say this applies to metastatic HER2-positive breast cancer. They say the survival gains were not accompanied by a significant rise in adverse events.

Why it is not certain yet

For neoadjuvant or adjuvant use, the range around the hazard ratio was very wide. It ran from 0.22 to 3.04. Results across studies varied before this analysis. A review can only be as good as the studies in it.

Source

Pertuzumab in HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials.

PubMed · PMID 43003957

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Metastatic breast cancer publications